BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 908034)

  • 1. Mechanism of tumor cell resistance to lysis by syngeneic lymphocytes.
    Fidler IJ; Bucana C
    Cancer Res; 1977 Nov; 37(11):3945-56. PubMed ID: 908034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity.
    Fidler IJ; Gersten DM; Budmen MB
    Cancer Res; 1976 Sep; 36(9 pt.1):3160-5. PubMed ID: 975082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extraction of immunogenic and suppressogenic antigens from variants of B16 melanoma exhibiting low or high metastatic potentials.
    LeGrue SJ; Hearn DR
    Cancer Res; 1983 Nov; 43(11):5106-11. PubMed ID: 6616449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple antigens related to the major envelope glycoprotein of murine leukemia virus expressed on B16 melanoma cells as targets of host immune response.
    Stackpole CW; Demsey A
    Invasion Metastasis; 1984; 4(1):28-46. PubMed ID: 6329988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of B16 melanoma lung colonization by syngeneic monoclonal antibodies.
    Herd ZL
    Cancer Res; 1987 May; 47(10):2696-703. PubMed ID: 3552203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in cytotoxic effects of activated murine peritoneal macrophages and J774 monocytic cells on metastatic variants of B16 melanoma.
    Miner KM; Klostergaard J; Granger GA; Nicolson GL
    J Natl Cancer Inst; 1983 Apr; 70(4):717-24. PubMed ID: 6339778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LY-2+ effectors cytotoxic for syngeneic tumor cells: generation by allogeneic stimulation and by supernatants from mixed leukocyte cultures.
    Hurrell SM; Zarling JM
    J Immunol; 1983 Aug; 131(2):1017-23. PubMed ID: 6223084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M; Orosz CG; Bach FH
    J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor cell and host properties affecting the implantation and survival of blood-borne metastatic variants of B16 melanoma.
    Fidler IJ; Nicolson GL
    Isr J Med Sci; 1978 Jan; 14(1):38-50. PubMed ID: 632082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced tumorigenicity of B16-F10 mouse melanoma cells transfected with mycobacterial antigen 85A.
    Tarrant JP; Walsh MJ; Blanchard MC; Lee TD; Hoskin DW; Giacomantonio CA
    Int J Oncol; 2004 Dec; 25(6):1693-9. PubMed ID: 15547707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological behavior of malignant melanoma cells correlated to their survival in vivo.
    Fidler IJ
    Cancer Res; 1975 Jan; 35(1):218-24. PubMed ID: 1109790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmentation of syngeneic tumor-specific immunity by semiallogeneic cell hybrids.
    Toffaletti DL; Darrow TL; Scott DW
    J Immunol; 1983 Jun; 130(6):2982-6. PubMed ID: 6189910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
    Lynch DH; Daynes RA; Hodes RJ
    J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages.
    Fogler WE; Fidler IJ
    Cancer Res; 1985 Jan; 45(1):14-8. PubMed ID: 3855280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
    Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
    J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state.
    Weinhold KJ; Wheelock EF
    Cancer Res; 1982 Sep; 42(9):3607-16. PubMed ID: 6179603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cytotoxic immunity indices of melanoma B16 growth in mice].
    Korosteleva TA; Veresova OV
    Vopr Onkol; 1980; 26(1):67-70. PubMed ID: 7355591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to tumor growth mediated by Listeria monocytogenes. Destruction of experimental malignant melanoma by LM-activated peritoneal and lymphoid cells.
    Youdim S
    J Immunol; 1976 Mar; 116(3):579-84. PubMed ID: 56396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity of antigens on UV radiation-induced antigenic tumor cell variants measured in vitro and in vivo.
    Hostetler LW; Romerdahl CA; Kripke ML
    Cancer Res; 1989 Mar; 49(5):1207-13. PubMed ID: 2465081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.